Lantern Pharma (LTRN) announced that the first patient has been enrolled and dosed in Taiwan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer who have progressed after receiving treatment with tyrosine kinase inhibitors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter